Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A

Description:

The report provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts. – PowerPoint PPT presentation

Number of Views:67

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A


1
Treating Refractory Hematological Malignancies -
Multiple Myeloma (MM) New Treatment Options
Driving In-Licensing and MA
One-Stop Shop for Business Information
2
Summary
The report provides an overview of the therapies
for Multiple Myeloma (Newly diagnosed - NDMM and
relapsed/ refractory - RRMM), unmet need, and
limitations of the current standard of care (SoC)
for relapsed and refractory MM pts. The report
highlights the competition and commercial
opportunity in pursuing this therapy area
Comprehensive list of the early and late stage
drugs in the clinic, their MoA and the companies
developing them. Detailed financial and
competitive analysis of the companies leading in
this field for this indication Celgene, Amgen
(post-acquisition of Onyx pharma), and MorphoSys
are available within this full report.
3
Key MA activities that have taken place in this
area in the last 5 years and a list of products
in early /late-stages of development available
for in-licensing are highlighted in the report.
This report is built using primary and secondary
research data and in-house proprietary
database. Reasons to buy the report Useful for
investors, Scientists, Business development
managers of Pharma companies with focus in
oncology to address the following- What are the
opportunities or new approaches to be deployed in
the RD of the company? List of validated and
new targets Commercial opportunity and
companies valuation.
4
KEY POINTS DISCUSSED IN THE REPORT Overview of
the Disease and Unmet need Drugs in the
pipeline NDMM RRMM Mechanism of Action (MoA)
and Clinical Stage of development  Comparative
Clinical data of Late-stage Pipeline in RRMM and
NDDM  Ongoing Clinical trial Details of Key
Drugs in Pipeline Key milestones MPA view on
the Future of the drugs in the late-stage
pipeline Launch Timeline and Commercial
Opportunity of Late-stage pipeline MA and
Licensing deals in the last 5 years In-licensing
and/or MA Opportunity
5
Table Of Contents
  1. Executive Summary
  2. Investment Drivers of The Select Companies
    Covered
  3. Multiple Myeloma (MM)
  4. Novel Targets including Monoclonal Antibodies And
    Small Molecules Offer In-Licensing Opportunity
  5. Ongoing Clinical Trial Details of Key Drugs in
    the Pipeline
  6. Key Milestones
  7. MPA View on the Future of the Drugs in the
    Late-Stage pipeline
  8. Detailed Company Analysis

6
Related Reports
  • Particle Size Analysis Market by Technology,
    Industry (Healthcare, Chemical, Petroleum,
    Mining, Mineral, Food) End User - Global
    Forecasts to 2018
  • Healthcare IT Integration Market by Products,
    Services, Applications (Hospitals, Radiology,
    Laboratory, Clinics) - Global Forecast to 2018
  • Romania Pharmaceuticals and Healthcare Report
  • Estonia Pharmaceuticals and Healthcare Report
  • Canada Pharmaceuticals and Healthcare Report

7
Custom Research
  • Incase the reports dont match your requirement
    then we can do a Custom Research for you. Our
    multifarious capabilities, cross-sector expertise
    and detailed knowledge of various markets, put us
    at a unique position to take up Custom Research
    demands of yours. We provide the specifications
    of the custom research job to a dedicated team
    comprising of researchers, analysts and industry
    experts, who have close experience and
    understanding of global markets, competitive
    landscapes, various business models, market
    shares, drivers, restraints and benchmarks.

8
  • To know more
  • Treating Refractory Hematological Malignancies -
    Multiple Myeloma (MM) New Treatment Options
    Driving In-Licensing and MA

Contact Us-Call India 91-22-27810772/73 Call
USA/Canada (Toll Free) 1-866-279-8368 Email id
info_at_bharatbook.com
About PowerShow.com